A retrospective analysis focusing on a group of patients with dual diagnosis treated by both mental health and substance use services

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 1479-1488

  Di Lorenzo, Rosaria ^a   Galliani, Agnese ^b   Guicciardi, Alessia ^b   Landi, Giulia ^b   Ferri, Paola ^b  

^a AUSL Modena   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

Dual diagnosis patients; Mental disorder and substance use co occurrence; Mental health and substance use services

Indexed keywords

ADULT; ADVERSE OUTCOME; ARTICLE; COMORBIDITY; DISEASE COURSE; FAMILY HISTORY; FEMALE; FOLLOW UP; HEALTH CARE NEED; HEALTH PROGRAM; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MENTAL HEALTH SERVICE; NURSING CARE; OUTCOME ASSESSMENT; OUTPATIENT; PERSONALITY DISORDER; PSYCHIATRIC DIAGNOSIS; PSYCHOTRAUMA; REHABILITATION CARE; RETROSPECTIVE STUDY; SEX DIFFERENCE; SOCIAL SUPPORT; SUBSTANCE USE;

EID: 84907326727     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S65896     Document Type: Article

References (55)

1. Brems C, Johnson ME, Wells RS, Burns R, Kletti N. Rates and sequelae of the coexistence of substance use and other psychiatric disorders. Int J Circumpolar Health. 2002;61(3):224-244.
2. Rigliano P. Doppia diagnosi. Tra tossicodipendenza e psicopatologia [Dual diagnosis. Between drug abuse and psychopathology]. Milan, Italy: Cortina Raffaello; 2004. Italian.
3. Regier DA, Farmer ME, Rae DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990;264(19):2511-2518.
4. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593-602.
5. Kessler RC, Chiu WT, Demler O, Merikangas KR, Walters EE. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6):617-627.
6. Maremmani I, Zolesi O, Aglietti M, Castrogiovanni P. Disturbi correlati a sostanze [Disorders related to substance]. In: Cassano GB, Pancheri P, Pavan L, et al, editors. Trattato Italiano di Psichiatria. 2nd ed. Milan, Italy: Masson; 1999:1352-1377. Italian.
7. Horsfall J, Cleary M, Hunt GE, Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): a review of empirical evidence. Harv Rev Psychiatry. 2009;17(1):24-34.
8. Rush B, Koegl CJ. Prevalence and profile of people with co-occurring mental and substance use disorders within a comprehensive mental health system. Can J Psychiatry. 2008;53(12):810-821.
9. Sterling S, Chi F, Hinman A. Integrating care for people with co-occurring alcohol and other drug, medical, and mental health conditions. Alcohol Res Health. 2011;33(4):338-349.
10. Canaway R, Merkes M. Barriers to comorbidity service delivery: the complexities of dual diagnosis and the need to agree on terminology and conceptual frameworks. Aust Health Rev. 2010;34(3): 262-268.
11. Munro I, Edward KL. Mental illness and substance use: an Australian perspective. Int J Ment Health Nurs. 2008;17(4):255-260.
12. Padwa H, Larkins S, Crevecoeur-Macphail DA, Grella CE. Dual diagnosis capability in mental health and substance use disorder treatment programs. J Dual Diagn. 2013;9(2):179-186.
13. Koob GF. The neurobiology of addiction: a neuroadaptational view relevant for diagnosis. Addiction. 2006;101 Suppl 1:23-30.
14. Wang TY, Lee SY, Chen SL, et al. Association between DRD2, 5-HTTLPR, and ALDH2 genes and specific personality traits in alcohol- and opiate-dependent patients. Behav Brain Res. 2013;250:285-292.
15. Gullo MJ, Loxton NJ, Dawe S. Impulsivity: Four ways five factors are not basic to addiction. Addict Behav. Epub 2014 Jan 16.
16. Ellingson JM, Fleming KA, Vergés A, Bartholow BD, Sher KJ. Working memory as a moderator of impulsivity and alcohol involvement: Testing the cognitive-motivational theory of alcohol use with prospective and working memory updating data. Addict Behav. Epub 2014 Jan 23.
17. Sansone RA, Watts DA, Wiederman MW. Borderline personality symptomatology and legal charges related to drugs. Int J Psychiatry Clin Pract. 2014;18(2):150-152.
18. Albein-Urios N, Martinez-Gonzalez JM, Lozano-Rojas O, Verdejo-Garcia A. Executive functions in cocaine-dependent patients with Cluster B and Cluster C personality disorders. Neuropsychology. 2014;28(1):84-90.
19. Conway KP, Compton W, Stinson FS, Grant BF. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiatry. 2006;67(2):247-257.
20. Angres D, Bologeorges S, Chou J. A two year longitudinal outcome study of addicted health care professionals: an investigation of the role of personality variables. Subst Abuse. 2013;7:49-60.
21. Krueger RF, Hicks BM, Patrick CJ, Carlson SR, Iacono WG, McGue M. Etiologic connections among substance dependence, antisocial behavior, and personality: modeling the externalizing spectrum. J Abnorm Psychol. 2002;111(3):411-424.
22. Mroziewicz M, Tyndale RF. Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addict Sci Clin Pract. 2010;5(2):17-29.
23. Wilson CS, Bennett ME, Bellack AS. Impact of family history in persons with dual diagnosis. J Dual Diagn. 2013;9(1):30-38.
24. Maniglio R. The impact of child sexual abuse on health: a systematic review of reviews. Clin Psychol Rev. 2009;29(7):647-657.
25. Wilson DR. Health consequences of childhood sexual abuse. Perspect Psychiatr Care. 2010;46(1):56-64.
26. Schäfer I, Fisher HL. Childhood trauma and psychosis - what is the evidence? Dialogues Clin Neurosci. 2011;13(3):360-365.
27. Sideli L, Mule A, La Barbera D, Murray RM. Do child abuse and maltreatment increase risk of schizophrenia? Psychiatry Investig. 2012;9(2):87-99.
28. Di Lorenzo R, Tomasini E, Ferri P. Psicosi e sostanze: problematiche cliniche e assistenziali in un campione di pazienti ricoverati in un reparto psichiatrico per acuti [Psychosis and substances: problems and clinical care in a sample of patients in a psychiatric department for acute care]. Psichiatria and Psicoterapia. 2008;27(1):1-15. Italian.
29. Goerke D, Kumra S. Substance abuse and psychosis. Child Adolesc Psychiatr Clin N Am. 2013;22(4):643-654.
30. Arias F, Szerman N, Vega P, et al. Abuse or dependence on cannabis and other psychiatric disorders. Madrid study on dual pathology prevalence. Actas Esp Psiquiatr. 2013;41(2):122-129.
31. Hambrecht M, Häfner H. Cannabis, vulnerability, and the onset of schizophrenia: an epidemiological perspective. Aust N Z J Psychiatry. 2000;34(3):468-475.
32. Morgan CJ, Curran HV. Effects of cannabidiol on schizophrenia-like symptoms in people who use cannabis. Br J Psychiatry. 2008; 192(4):306-307.
33. Zammit S, Allebeck P, Andreasson S, Lundberg I, Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 2002;325(7374):1199.
34. Winklbaur B, Ebner N, Sachs G, Thau K, Fischer G. Substance abuse in patients with schizophrenia. Dialogues Clin Neurosci. 2006; 8(1):37-43.
35. Suh JJ, Ruffins S, Robins CE, Albanese MJ, Khantzian EJ. Self-medication hypothesis: connecting affective experience and drug choice. Psychoanal Psychol. 2008;25(3):518-532.
36. Li T, Liu X, Zhao J, et al. Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects. Am J Med Genet. 2002;114(3):329-335.
37. Pettinati HM, O'Brien CP, Dundon WD. Current status of co-occurring mood and substance use disorders: a new therapeutic target. Am J Psychiatry. 2013;170(1):23-30.
38. Sánchez-Peña JF, Alvarez-Cotoli P, Rodríguez-Solano JJ. Psychiatric disorders associated with alcoholism: 2 year follow-up of treatment. Actas Esp Psiquiatr. 2012;40(3):129-135.
39. Lucchini A, Bravin S, Cataldini R, et al. Depressione e Dipendenze Patologiche: L'esperienza dei Servizi Territoriali [Depression and Pathological Addictions: The Experience of the Territorial Services]. Milan, Italy: Franco Angeli; 2004. Italian.
40. Maremmani AG, Rovai L, Bacciardi S, et al. The long-term outcomes of heroin dependent-treatment-resistant patients with bipolar 1 comorbidity after admission to enhanced methadone maintenance. J Affect Disord. 2013;151(2):582-589.
41. Sani G, Kotzalidis GD, Vöhringer P, et al. Effectiveness of short-term olanzapine in patients with bipolar I disorder, with or without comorbidity with substance use disorder. J Clin Psychopharmacol. 2013; 33(2):231-235.
42. Heffner JL, Anthenelli RM, Adler CM, Strakowski SM, Beavers J, DelBello MP. Prevalence and correlates of heavy smoking and nicotine dependence in adolescents with bipolar and cannabis use disorders. Psychiatry Res. 2013;210(3):857-862.
43. Gros DF, Milanak ME, Brady KT, Back SE. Frequency and severity of comorbid mood and anxiety disorders in prescription opioid dependence. Am J Addict. 2013;22(3):261-265.
44. Pacek LR, Storr CL, Mojtabai R, et al. Comorbid alcohol dependence and anxiety disorders: a national survey. J Dual Diagn. 2013;9(4).
45. Brady KT, Sinha R. Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. Am J Psychiatry. 2005; 162(8):1483-1493.
46. Pruessner JC, Champagne F, Meaney MJ, Dagher A. Dopamine release in response to a psychological stress in humans and its relationship to early life maternal care: a positron emission tomography study using [11C]raclopride. J Neurosci. 2004;24(11):2825-2831.
47. Post RM, Kalivas P. Bipolar disorder and substance misuse: pathological and therapeutic implications of their comorbidity and cross-sensitisation. Br J Psychiatry. 2013;202(3):172-176.
48. Ministero del Lavoro, della Salute e delle Politiche Sociali. La Classificazione delle Malattie, dei Traumatismi, degli Interventi Chirurgici e delle Procedure Diagnostiche e Terapeutiche: Versione Italiana della ICD-9-CM [International Classification of Diseases, 9th revision, Clinical Modification, 2007]. Rome, Italy: Istituto Poligrafico e Zecca dello Stato, Libreria dello Stato; 2008. Italian.
49. Rush AJ Jr, First MB, Blacker D. Handbook of Psychiatric Measures. 2nd ed. Washington, DC: American Psychiatric Publishing; 2007.
50. Luborsky L. Clinicians' judgments of mental health: a proposed scale. Arch Gen Psychiatry. 1962;7(6):407-417.
51. Stata Corp LP. Stata Statistical Software: Release 12. College Station, TX: Stata Corp LP, 2011.
52. Arcos-Burgos M, Vélez JI, Solomon BD, Muenke M. A common genetic network underlies substance use disorders and disruptive or externalizing disorders. Hum Genet. 2012;131(6):917-929.
53. Connor JP, Gullo MJ, Chan G, Young RM, Hall WD, Feeney GF. Polysubstance use in cannabis users referred for treatment: drug use profiles, psychiatric comorbidity and cannabis-related beliefs. Front Psychiatry. 2013;4:79.
54. Sher KJ, Trull TJ. Substance use disorder and personality disorder. Curr Psychiatry Rep. 2002;4(1):25-29.
55. Sansone RA, Sansone LA. Substance use disorders and borderline personality: common bedfellows. Innov Clin Neurosci. 2011; 8(9):10-13.